China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approvals from the National Medical Products Administration (NMPA) for its six novel drug candidates targeting solid tumors.
Drug Candidates
The approved drugs include the EZH2 inhibitor SHR2554, PD-L1 antibody adebrelimab, SHR-1701 injection, a PD-L1/TGF-βRII bifunctional fusion protein, and three antibody-drug conjugates (ADCs): SHR-A1811 targeting HER2, SHR-A2102 targeting Nectin-4, and SHR-A1904 targeting Claudin18.2.
Therapeutic Strategy
Some of these drug candidates will be explored in combination therapies to enhance treatment efficacy for solid tumors.-Fineline Info & Tech
